Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

Completed · Phase 4 · Has a placebo group

Conditions studied: Depressive Disorder, Parkinson Disease

In brief

This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.

Key facts

Study ID

NCT00304161

Run by

University of Pennsylvania

People needed

55

Starts

2004-07-01

Expected to finish

2008-12-01

Last updated by the study team

2017-01-30

Who can join

Age: 30 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of idiopathic Parkinson's disease
• IDS score greater than 21
• Mini-Mental State Examination (MMSE) score greater than 15

You may not qualify if…

• Recent deep brain stimulation
• Currently participating in an antidepressant trial at a less than adequate dose and duration
• Severe depression or depression with suicide ideation
• History of liver toxicity
• Unstable medical disease or comorbid psychiatric disease

Where it is running

• Philadelphia Veterans Affairs Medical Center — Philadelphia, Pennsylvania, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.